About
Peter Fromen is the Chief Executive Officer of biomodal, formerly Cambridge Epigenetix, a genomics and multiomics company. Before biomodal, he was Chief Commercial Officer at PacBio and previously held multiple leadership roles at Illumina, including investor relations, market development, enterprise sales, and population genomics. The apparent "Cellanome" association likely comes from biomodal's board page, where Cellanome CEO Omead Ostadan is listed as a director alongside Fromen.
Areas of interest
genomicsmultiomicsepigeneticssingle-cell biologyprecision medicineageingcancer researchneurodegenerative diseaseliquid biopsy